International Society

Process Safety Technical Consultant Ehab Tayel joins the Hargrove Controls & Automation Process Safety Team

Retrieved on: 
Wednesday, April 10, 2024
Al-Azhar University, Electrical engineering, International Society, Safety, IPL, SIL4, Certification, Electricity, IEC, Functional safety, SFS, Growth, Engineering, Environment, Bachelor, SRS, FS, SIL, ISA, EPC, Risk assessment, Knowledge, Risk management

MOBILE, Ala., April 10, 2024 /PRNewswire-PRWeb/ -- Hargrove Controls & Automation, a leading industrial automation system integrator and a subsidiary of global EPC firm Hargrove Engineers & Constructors, announced today that Ehab Tayel joins their team as a Process Safety Technical Consultant. In his new role, Tayel will enhance the capabilities of Hargrove Controls & Automation's process safety team and cultivate new and existing client relationships in the Houston Ship Channel area.

Key Points: 
  • Ehab Tayel, TÜV (Rheinland), FSE, CFSE, brings nearly two decades of process safety experience and a passion for the safety lifecycle to Hargrove Controls & Automation's process safety team in the Pasadena, TX office.
  • MOBILE, Ala., April 10, 2024 /PRNewswire-PRWeb/ -- Hargrove Controls & Automation , a leading industrial automation system integrator and a subsidiary of global EPC firm Hargrove Engineers & Constructors , announced today that Ehab Tayel joins their team as a Process Safety Technical Consultant.
  • In his new role, Tayel will enhance the capabilities of Hargrove Controls & Automation's process safety team and cultivate new and existing client relationships in the Houston Ship Channel area.
  • "We are excited to welcome Ehab to the process safety team at Hargrove C&A," said Chet S. Barton, P.E., FS Exp (TÜV Rheinland) , Process Safety Industry Leader at Hargrove Controls & Automation.

TFF Pharmaceuticals Announces Updated Data from the Tacrolimus Inhalation Powder (TFF TAC) and Voriconazole Inhalation Powder (TFF VORI) Clinical Programs

Retrieved on: 
Wednesday, March 27, 2024
Principal, Annual, Fungal infection, TFF, COVID, Intubation, International Society, Part, Patient, Biomarker, IPA, Spirometry, EAP, Mortality, Lung transplantation, Microsoft Access, Potential, Safety, Kidney, Heart, Pharmaceutical industry

FORT WORTH, Texas , March 27, 2024 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP) (“the Company”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced updated data from the Tacrolimus Inhalation Powder (TFF TAC) and Voriconazole Inhalation Powder (TFF VORI) clinical programs.

Key Points: 
  • “Based on the totality of these clinical data, we believe TFF TAC and TFF VORI have the potential to establish a new and significantly improved form of delivery for these two life-saving medicines.
  • The updated safety and efficacy data are based on the cutoff date of March 8, 2024.
  • The ongoing Phase 2 trial of TFF TAC is an open-label study in lung transplant patients who require reduced tacrolimus blood levels due to kidney toxicity.
  • The Company will host a conference call today at 4:30 pm Eastern Time, to discuss updated data for the Tacrolimus Inhalation Powder (TFF TAC) and Voriconazole Inhalation Powder (TFF VORI) clinical programs.

CareDx and Collaborators Present Latest Cardiothoracic Advancements at the 2024 International Society for Heart and Lung Transplantation Meeting

Retrieved on: 
Tuesday, April 9, 2024
Health, Surgery, Genetics, Managed Care, General Health, Cardiology, Biotechnology, Patient, International Society, Caregiver, White, Transplant, Columbia University, University, University of Colorado, Lung transplantation, Heart transplantation, Abstract, Lung, Heart, NYU Langone Health, Stanford University, University Health Network, MAS, Loyola University, Medical device

CareDx, along with study collaborators from leading transplant centers, will present cutting-edge developments that underscore the clinical significance of CareDx’s cardiothoracic portfolio.

Key Points: 
  • CareDx, along with study collaborators from leading transplant centers, will present cutting-edge developments that underscore the clinical significance of CareDx’s cardiothoracic portfolio.
  • This includes AlloSure Heart, AlloMap Heart, HeartCare, AlloSure Lung, and AiCAV (in development); featured in over 25 oral presentations, posters, and two symposia.
  • These presentations will highlight real-world applications driving advancements in heart and lung transplantation.
  • “We are proud to have a leading presence once again at this pivotal heart and lung transplant meeting.

Natera Announces New Data From Two Studies Extending the Clinical Validation of Its Prospera™ Heart dd-cfDNA Test for Heart Transplant Recipients

Retrieved on: 
Monday, April 8, 2024
Research, Surgery, Genetics, Clinical Trials, Cardiology, Biotechnology, Health, General Health, Science, Biopsy, Reward, Plasma, International Society, Cohort (statistics), Physician, Risk, AUC, Nucleic acid thermodynamics, Patient, Journal, DNA, Lung transplantation, Heart transplantation, MD, NIH, NTRA, Hospital, Molecule, Bangladesh Technical Education Board, Medicare, Oportunidades, Annual general meeting, NPV

“We are encouraged by the results of these two prospective studies,” said Sangeeta Bhorade, MD, chief medical officer of organ health at Natera.

Key Points: 
  • “We are encouraged by the results of these two prospective studies,” said Sangeeta Bhorade, MD, chief medical officer of organ health at Natera.
  • That study showed the Prospera Heart test had an overall area under the curve (AUC) of 0.86 for identifying acute rejection in over 800 samples from 200 adults with heart transplants.
  • The DTRT-2 (DNA-Based Transplant Rejection Test) study, published recently in Pediatric Transplantation , was sponsored by the National Institutes of Health (NIH).
  • A total of 487 samples from 160 heart transplant recipients were evaluated, of which 78 were pediatric and 82 were adult patients.

Zeevo Group’s Client Success Team Gets Boost With New Member Megan King

Retrieved on: 
Tuesday, April 9, 2024
Technology, Transportation, Aerospace, Travel, Manufacturing, Finance, Other Transport, Consulting, Banking, Professional Services, Air, Transport, Other Technology, Logistics, Supply Chain Management, Aircraft, Transport aircraft, Amazon Air, CALC, Information technology, International Society, Trinity College, Executive, St. Norbert College, Aviation, ISTAT, Trinity College Dublin, Multimedia, Marketing, Executive director

Zeevo Group LLC ("Zeevo"), an operations, finance, and information technology consulting services firm, welcomed Megan King as a new member of its Client Success Team.

Key Points: 
  • Zeevo Group LLC ("Zeevo"), an operations, finance, and information technology consulting services firm, welcomed Megan King as a new member of its Client Success Team.
  • "With her extensive network of relationships with aircraft leasing companies, airlines, manufacturers, and maintenance service providers, she is the perfect fit for our Client Success Team."
  • King joins Zeevo from Smithbucklin following a ten-year-plus tenure at the association management company that delivers management and specialized services to trade and professional associations.
  • "I am thrilled and honored to be joining the elite team at Zeevo," said Megan King, a newly appointed consultant of Zeevo Group.

Calliditas Therapeutics to Present Nefecon Data at the ISN World Congress of Nephrology April 13 - 16 in Buenos Aires

Retrieved on: 
Monday, April 8, 2024
Diabetes, Anaphylaxis, IgA nephropathy, Glaucoma, CYP3A4, Dermatitis, Patient, Parasitism, Indinavir, Budesonide, Ritonavir, Quality of life, Peripheral edema, UPCR, Drug interaction, Vaccine, Saquinavir, Erythromycin, Congress, White, Risk, Headache, Spasm, Ketoconazole, Immunoglobulin A, Liver, Adrenal insufficiency, Immune system, Prediabetes, Proteinuria, Hypertension, Contraindication, Arthralgia, Ciclosporin, International Society, Immunosuppression, KOL, Acne, Infection, EGFR, Measles, Miscarriage, ISN, Hypersensitivity, Pregnancy, HPA, Chickenpox, Fetus, Birth, Itraconazole, CALT, Upper respiratory tract infection, Osteoporosis, Kidney, Cataract, Tropical ulcer, Pharmaceutical industry

The ISN World Congress of Nephrology will be held in Buenos Aires, Argentina April 13-16, 2024.

Key Points: 
  • The ISN World Congress of Nephrology will be held in Buenos Aires, Argentina April 13-16, 2024.
  • Presentations will highlight the eGFR results found in patients on Nefecon as well as the data on quality of life during the trial.
  • There will also be a presentation on the subanalysis evaluating benefits of Nefecon for patients with lower levels of UPCR.
  • The congress will include a symposium, Evolving Landscape of eFGR and Proteinuria Surrogate Markers in IgA Nephropathy, moderated by KOL Richard Lafayette, M.D., F.A.C.P.

Calliditas Therapeutics to Present Nefecon Data at the ISN World Congress of Nephrology April 13 - 16 in Buenos Aires

Retrieved on: 
Monday, April 8, 2024
Diabetes, Anaphylaxis, IgA nephropathy, Glaucoma, CYP3A4, Dermatitis, Patient, Parasitism, Indinavir, Budesonide, Ritonavir, Quality of life, Peripheral edema, UPCR, Drug interaction, Vaccine, Saquinavir, Erythromycin, Congress, White, Risk, Headache, Spasm, Ketoconazole, Immunoglobulin A, Liver, Adrenal insufficiency, Immune system, Prediabetes, Proteinuria, Hypertension, Contraindication, Arthralgia, Ciclosporin, International Society, Immunosuppression, KOL, Acne, Infection, EGFR, Measles, Miscarriage, ISN, Hypersensitivity, Pregnancy, HPA, Chickenpox, Fetus, Birth, Itraconazole, CALT, Upper respiratory tract infection, Osteoporosis, Kidney, Cataract, Tropical ulcer, Pharmaceutical industry

The ISN World Congress of Nephrology will be held in Buenos Aires, Argentina April 13-16, 2024.

Key Points: 
  • The ISN World Congress of Nephrology will be held in Buenos Aires, Argentina April 13-16, 2024.
  • Presentations will highlight the eGFR results found in patients on Nefecon as well as the data on quality of life during the trial.
  • There will also be a presentation on the subanalysis evaluating benefits of Nefecon for patients with lower levels of UPCR.
  • The congress will include a symposium, Evolving Landscape of eFGR and Proteinuria Surrogate Markers in IgA Nephropathy, moderated by KOL Richard Lafayette, M.D., F.A.C.P.

Questex’s IHIF EMEA 2024: The Meeting Place of Hospitality Innovators and Game-Changers

Retrieved on: 
Monday, March 25, 2024
CBRE, AXA, Starwood Capital Group, ISHC, InterContinental, International Society, Partnership, ESG, Travel, Tokyo Disney Resort, Booking.com, Hospitality, Forum, Real assets, IHG Hotels & Resorts, Invesco, Heart, HSBC, Accor, KSL Capital Partners, Young, Groupe du Louvre, Barclays, Management

LONDON, March 25, 2024 (GLOBE NEWSWIRE) -- Questex’s International Hospitality Investment Forum EMEA (IHIF EMEA) today announces its highly anticipated return to Berlin 15 to 17 April 2024.

Key Points: 
  • LONDON, March 25, 2024 (GLOBE NEWSWIRE) -- Questex’s International Hospitality Investment Forum EMEA (IHIF EMEA) today announces its highly anticipated return to Berlin 15 to 17 April 2024.
  • Held at the InterContinental and Pullman hotels, this year's forum promises to deliver unparalleled insights, deal-making opportunities, and networking prospects for the global hospitality industry.
  • With a focus on navigating the evolving macro-economic landscape, IHIF EMEA 2024 will delve into key themes shaping the future of hospitality investment.
  • For more information about IHIF EMEA 2024 and to register for the event, visit IHIF EMEA website .

Konica Minolta Healthcare Sponsors SPIE Best Student Paper Award

Retrieved on: 
Thursday, March 14, 2024
Medical physics, Clinical research, Physics, Konica Minolta, International Society, Optics, SPIE, Science, Grace, University, Education, Patient, Research, History, Facilitation, Doctor of Philosophy, Minolta, University of Wisconsin–Madison, Iodine, Biological engineering, Signal-to-noise ratio, Health, Medical imaging

WAYNE, N.J., March 14, 2024 (GLOBE NEWSWIRE) -- Konica Minolta Healthcare Americas congratulates the winner and runners-up of the Best Student Paper Award given by the International Society for Optics and Photonics (SPIE) at its 2024 Medical Imaging Symposium in San Diego.

Key Points: 
  • WAYNE, N.J., March 14, 2024 (GLOBE NEWSWIRE) -- Konica Minolta Healthcare Americas congratulates the winner and runners-up of the Best Student Paper Award given by the International Society for Optics and Photonics (SPIE) at its 2024 Medical Imaging Symposium in San Diego.
  • With a history of 150 years of innovation, Konica Minolta is committed to fostering the development of advanced technologies to visualize what is not visible.
  • As a multinational company invested in research to deliver innovations in imaging technologies, Konica Minolta sponsored the award as part of its continued commitment to education and support of young scientists in medical imaging.
  • “Konica Minolta is proud to be a sponsor of the SPIE Medical Imaging Symposium and excited to support research and innovation in basic science applied to medical imaging,” says John Sabol, Clinical Research Manager, Konica Minolta Healthcare.

INmune Bio CSO and Co-Founder Mark Lowdell, Ph.D. Receives The ISCT Career Achievement Award in Cell and Gene Therapy

Retrieved on: 
Wednesday, March 13, 2024
ICST, ISCT, International Society, Disease, Science, Career Achievement Award, Patient, Knowledge, Lead, Gene, University College London, GMP, CGT, CSO, Vaccine

Boca Raton, Florida, March 13, 2024 (GLOBE NEWSWIRE) --  INmune Bio Inc. (NASDAQ: INMB) (the “Company”),  a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, announces its Chief Scientific Officer and Co-Founder Mark Lowdell, Ph.D. has been awarded the Career Achievement Award in Cell and Gene Therapy by the International Society of Cell & Gene Therapy (ISCT), which the organization considers its highest honor. The award was announced as part of the annual ICST Major Awards announcement. Dr. Lowdell will receive the award during the organization’s annual meeting in Vancouver on May 29, 2024.

Key Points: 
  • The award was announced as part of the annual ICST Major Awards announcement.
  • Dr. Lowdell will receive the award during the organization’s annual meeting in Vancouver on May 29, 2024.
  • The ISCT is the elite organization in the field of cell and gene therapy,” said R.J. Tesi, M.D., INmune Bio’s Chief Executive Officer.
  • “I am honored to receive this most prestigious award in recognition of my life’s work and wish to thank the members of the ISCT.